BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29620685)

  • 1. EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study.
    Cupit-Link MC; Nageswara Rao A; Warad DM; Rodriguez V; Khan S
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):e473-e478. PubMed ID: 29620685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG; Tan MYQ; Quak SH; Aw MM
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.
    Neumann T; Schneidewind L; Thiele T; Pink D; Schulze M; Schmidt C; Krüger W
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
    Patel K; Parmar S; Shah S; Shore T; Gergis U; Mayer S; van Besien K
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):456-61. PubMed ID: 26524732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
    Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
    Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
    Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
    Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
    Front Immunol; 2020; 11():620891. PubMed ID: 33664733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS
    Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single-center study.
    Tsoumakas K; Giamaiou K; Goussetis E; Graphakos S; Kossyvakis A; Horefti E; Mentis A; Elefsiniotis I; Pavlopoulou ID
    Transpl Infect Dis; 2019 Aug; 21(4):e13095. PubMed ID: 30993823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-free maintenance immunosuppression using alemtuzumab in pediatric kidney transplantation: Long-term longitudinal follow-up.
    Jain A; Daoud D; Kees-Folts D; Freeman MA; Butt F; Abendroth CS; Shike H; Kadry Z
    Pediatr Transplant; 2022 Mar; 26(2):e14173. PubMed ID: 34687570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience.
    Bernard F; Uppungunduri CRS; Meyer S; Cummins M; Patrick K; James B; Skinner R; Tewari S; Carpenter B; Wynn R; Veys P; Amrolia P;
    Br J Haematol; 2021 May; 193(4):804-813. PubMed ID: 33855694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.
    Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Uchida N; Maeda T; Mori T; Kanda Y; Kondo T; Shiratori S; Miyakoshi S; Ishiyama K; Ikegame K; Matsuhashi Y; Tanaka J; Ichinohe T; Atsuta Y; Ogata M; Suzuki R
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1441-1449. PubMed ID: 30794929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.